Journal
EUROPEAN JOURNAL OF CANCER
Volume 44, Issue 1, Pages 131-141Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ejca.2007.10.011
Keywords
p53; p73; ovarian cancer; splice variants
Categories
Funding
- NATIONAL CANCER INSTITUTE [R01CA093853] Funding Source: NIH RePORTER
- Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom
- NCI NIH HHS [R01 CA093853, R01 CA093853-05S2] Funding Source: Medline
Ask authors/readers for more resources
The p53 gene has been investigated for its role in epithelial ovarian cancer but data collected until now are contradictory. The evidence that p53 belongs with p63 and p73 to a family of transcription factors re-opened interest in this gene family. Here, we used quantitative real time RT-PCR to determine expression levels of TAp53, TAp73 and their N-terminal splice variants in a cohort of 169 ovarian cancer patients with stage I and stage III disease. The TAp73 levels in stage III biopsies differed by 100-fold depending on the p53 status and overall survival appears to be significantly related to Delta Np73 expression. Kaplan-Meyer analyses did not suggest a correlation between overall survival and levels of TAp73, Delta Np73 or the Delta Np73/TAp73 ratio. In conclusion, these data suggest that at least in our patient cohort p53 and p73 expression levels are not correlated to malignant progression of ovarian cancer. They might, however, play a role in tumour initiation. (c) 2007 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available